The Race to Develop More Medicines Like the New Pancreatic Cancer Drug
Scientists are investigating why the survival benefits of daraxonrasib fade over time after its August approval for pancreatic cancer. While the drug provides patients with more time, the medical community is now shifting focus toward early disease treatment to maximize survival rates. This effort follows a broader industry trend of using AI and biotechnology to develop therapies targeting RAS gene mutations in one of the most lethal cancer types.
Listen to Live Briefing
Real-time synthesized voice briefing · Live Feeds Desk
- ✓ The FDA cleared daraxonrasib in August.
- ✓ Daraxonrasib targets specific gene mutations to treat pancreatic cancer.
What changed
Researchers are now analyzing why daraxonrasib's clinical benefits diminish and exploring early intervention strategies.
Live updates
-
Researchers Study Daraxonrasib Efficacy Loss and Early Treatment Options
Scientists are investigating why the survival benefits of daraxonrasib fade over time after its August approval for pancreatic cancer. While the drug provides patients with more time, the medical community is now shifting focus toward early disease treatment to maximize survival rates. This effort follows a broader industry trend of using AI and biotechnology to develop therapies targeting RAS gene mutations in one of the most lethal cancer types.
Why it matters
Daraxonrasib was developed by Revolution Medicines and tested by Dana-Farber Cancer Institute. Its approval relied on RASolute 302 survival data and five decades of public funding and basic science.
What is confirmed
- The FDA cleared daraxonrasib in August.
- Daraxonrasib targets specific gene mutations to treat pancreatic cancer.
Still unconfirmed
- Researchers are seeking ways to increase survival by treating pancreatic cancer earlier.
- Scientists are racing to determine why the benefits of daraxonrasib fade.
What to watch next
- Publication of data explaining the cause of daraxonrasib efficacy loss
- Clinical trial results for early-intervention pancreatic cancer treatments
confidence 90%Sources used for this update (5)
- www.nature.com — Can pancreatic cancer be stopped in its tracks? Radical tactic raises hopes
- www.newser.com — How a Promising Pancreatic Cancer Drug Loses Its Punch - Newser
- townsendletter.com — How To Take Back Control of Your Life - Townsend Letter
- acibademinternational.com — Leukemia vs Lymphoma Treatment Differences Explained
- www.medicaldaily.com — An Angry Call with Her Health Insurer Sent a 63-Year-Old Woman to Cardiac Care with Broken Heart Syndrome....
-
FDA Approval of Daraxonrasib Opens Path for RAS-Targeted Pancreatic Cancer Therapy
The FDA approved daraxonrasib, a drug developed by Revolution Medicines and tested by Dana-Farber Cancer Institute, to treat pancreatic cancer by targeting specific gene mutations. The approval follows the release of RASolute 302 survival data and marks the culmination of 50 years of basic science and public funding. This success has triggered a broader effort by pharmaceutical and tech companies to use AI and biotech to create similar RAS-targeted therapies, aiming to treat one of the deadliest forms of cancer.
Why it matters
Pancreatic cancer has long been difficult to treat because its primary drivers were considered elusive. Daraxonrasib targets the RAS gene mutations that cause abnormal cell growth. This breakthrough provides a blueprint for developing other targeted oncology medicines.
What is confirmed
- The FDA approved daraxonrasib for the treatment of pancreatic cancer.
- Revolution Medicines developed daraxonrasib and Dana-Farber Cancer Institute conducted the testing.
- The drug targets gene mutations that drive abnormal cell growth in pancreatic cancer.
What to watch next
- Publication of long-term safety data from the RASolute 302 trials
- Clinical trial results for subsequent RAS-targeted therapies in development
confidence 100%Sources used for this update (8)
- www.onclive.com — Daraxonrasib Approval Signals a New Era for RAS-Targeted ...
- jen.jiji.com — Former vice-president of the Sicilian Region Gaetano Armao investigated for corruption, Public Prosecutor's Office requests arrest
- jen.jiji.com — Schlein warns allies: "One is not worth one, PD got double the votes of the others"
- www.medscape.com — How Scientists Finally Cracked RAS in Pancreatic Cancer - Today on Medscape
- www.aacr.org — Beyond Hangovers: Binge Drinking and the Risk of Early-onset Breast and Colorectal Cancers
- www.medicaldaily.com — Chocolate Chips Hiding Pills at a Rave Left a 19-Year-Old With an Upside-Down Broken Heart and Artery Clo....
- jen.jiji.com — ATP Beijing, Djokovic beats Zverev in quarters and does Sinner a favor
- theconversation.com — Here’s how scientists aim to speed up drug development for treating new viruses
-
Pancreatic Cancer Drug Sparks Race for More Medicines
A new pancreatic cancer drug, daraxonrasib, has shown significant promise and was approved by the FDA ahead of schedule. Developed by Revolution Medicines and tested by Dana-Farber Cancer Institute, it targets specific gene mutations driving abnormal cell growth in pancreatic cancer. This breakthrough has sparked a race to develop more medicines like it, with big tech and pharmaceutical companies exploring AI and biotech innovations to tackle cancer.
Why it matters
Pancreatic cancer remains a challenging and often deadly disease, with current treatments having limited effectiveness. The development of daraxonrasib offers new hope for patients and has triggered a surge of interest in similar treatments. The use of AI and collaborations between Western and Chinese biotech firms are expected to accelerate the discovery of new cancer medicines.
What is confirmed
- Daraxonrasib was approved by the FDA more than six months ahead of schedule.
- The drug works by blocking specific gene mutations thought to drive abnormal cell growth in pancreatic cancer.
- Western drugmakers are joining forces with Chinese innovators on the frontlines of the fight against cancer.
- Lung cancer is still the top cancer killer, but new developments are shifting what the future might hold for patients.
Still unconfirmed
- Big tech claims AI can find a cure for cancer.
What to watch next
- Further test results for daraxonrasib
- FDA decisions on similar treatments
- Advances in AI-driven cancer research
confidence 90%Sources used for this update (8)
- www.theguardian.com — Big tech says AI can find a cure for cancer. So where is it?
- www.theepochtimes.com — What Happens to Your Body When You Drink Coffee Regularly
- www.nprillinois.org — From professor to patient: One man's journey on the frontier of lung cancer treatment | NPR Illinois
- acibademinternational.com — Myelofibrosis Infection, Bleeding and Transfusion Warning Signs
- cepa.org — Sourcing the Next Blockbuster: Big Pharma Uses Chinese Biotech - CEPA
- creators.yahoo.com — He was a Division I athlete who never smoked. Now David Cornbrooks is a patient in the lung cancer vaccin....
- www.wbur.org — How an Mass. researcher's lab made a breakthrough in pancreatic cancer treatment
- gizmodo.com — This Pill Will Change Cancer Treatment Forever - Gizmodo
-
Cycling World Championships Men's Road Race Held in Montreal
The men's road race at the Cycling World Championships occurs today, Sunday, September 27, in Montreal, Canada. Tadej Pogacar misses the event due to an injury sustained from a fall during the Vuelta, preventing him from defending his title. Remco Evenepoel enters the race as the favorite following his earlier victory in the time trial. Riders contest a 273.7-kilometer course featuring an elevation gain of 3,800 meters, concluding with twelve final laps containing multiple climbs before an uphill finish on Avenue du Parc.
Why it matters
The annual world championship event brings together elite cyclists to compete for the national-team-style title on a challenging urban circuit. Tactical battles typically concentrate on the closing laps after an initial flat section that encourages early breakaways. Slovenia's top contender cannot participate, altering the competitive dynamic for the peloton.
What is confirmed
- The men's road race takes place today, Sunday, September 27, in Montreal, Canada.
- Tadej Pogacar is unable to defend his title due to an injury from a fall during the Vuelta.
- Remco Evenepoel is the favorite after winning the time trial.
- The race route totals 273.7 kilometers with an average elevation gain of 3800 meters.
What to watch next
- The official finish of the men's road race on Avenue du Parc
- The crowning of the new world champion in Montreal
confidence 100%Sources used for this update (2)
- omaha.com — Top Journal Star photos and videos for September 2026
- jen.jiji.com — Cycling World Championships, today the men's road race: schedule, route and where to watch it on TV (free-to-air)
-
Medical Research Faces Funding Threats and New Treatment Demands
Medical research leadership faces severe funding threats under proposals from Donald Trump and Russ Vought, putting future cures and American innovation at risk. Meanwhile, the Italian Vitiligo Association is pushing for accelerated recognition and institutional access to new treatments following the European approval of upadacitinib for non-segmental vitiligo. At the same time, scientific understanding of pathology continues to evolve with the identification of more than 20 distinct pathways of controlled cell death, moving far beyond traditional necrosis and apoptosis models.
Why it matters
The pressure to accelerate new therapies coincides with broader scientific advancements in understanding cellular mechanisms. Simultaneously, political threats to research funding jeopardize the pipeline required to develop targeted treatments and diagnostic tools for complex diseases.
What is confirmed
- The European Union granted approval for upadacitinib as a systemic drug for non-segmental vitiligo.
- Davide Rossetti serves as president of the Italian Vitiligo Association.
Still unconfirmed
- Future medical cures and American innovation are in jeopardy due to a funding scheme proposed by Donald Trump and Russ Vought.
What to watch next
- Institutional decisions regarding medical research funding and National Institutes of Health budgets
- Implementation of new regulatory pathways for vitiligo treatments in European markets
confidence 80%Sources used for this update (5)
- jen.jiji.com — William Shatner at 95 surprises everyone, the legendary Captain Kirk debuts in metal
- jen.jiji.com — Rossetti (Aiv): "Accelerate recognition of vitiligo and access to new treatments"
- www.quiverquant.com — Quiver News
- note.com — There Is More Than One Way to Die! The Mysteries of Life Revealed by Over 20 Types of 'Diverse Cell Death'
- www.thebulwark.com — This Is a Five-Alarm Fire for Medical Research
-
AI-Enhanced Blood Test Shows Promise for Early Pancreatic Cancer Detection
An international study indicates that an investigational blood test using AI and biomarkers may detect pancreatic cancer earlier. This development supports the goal of identifying the disease before invasive cancer develops. These diagnostic efforts run parallel to the development of targeted therapies like daraxonrasib and funding initiatives from PanCAN. While early detection remains a primary hurdle, the integration of artificial intelligence into biomarker screening offers a potential path toward identifying patients before the disease reaches late stages where treatment is most difficult.
Why it matters
Pancreatic cancer is often diagnosed at advanced stages. Early detection is critical for improving survival rates. Current research focuses on combining blood-based screening with targeted medications.
Still unconfirmed
- An investigational blood test combining AI and biomarkers may help detect pancreatic cancer earlier
What to watch next
- Clinical trial results validating the AI biomarker test
- FDA approval status for daraxonrasib
- Additional grant awards from the All Together We Can campaign
confidence 70%Sources used for this update (2)
- www.medicalnewstoday.com — AI-enhanced biomarker blood test may detect pancreatic cancer earlier, study suggests
- www.labiotech.eu — WCLC 2026: The lung cancer drug development readouts that caught our eye
-
PanCAN Awards 2026 Grants as Early Detection Research Advances
PanCAN has awarded 12 research grants through two programs as part of the All Together We Can campaign to accelerate pancreatic cancer research. This funding arrives while the field pursues early detection methods, such as blood tests, to identify the disease before it reaches the late stages where treatment is most difficult. These efforts complement the existing push for targeted therapies like daraxonrasib, which recently received breakthrough therapy designation for first-line metastatic pancreatic cancer.
Why it matters
Pancreatic cancer is often diagnosed in late stages, limiting treatment efficacy. Recent milestones include Rasonque, which doubled median survival rates by targeting RAS mutations. The industry is now shifting toward a combination of early screening and personalized vaccines.
What is confirmed
- PanCAN announced 12 grants through two programs as part of the All Together We Can campaign.
- Pancreatic cancer is typically detected in its latest stages, making it harder to treat.
What to watch next
- Clinical trial results for early-detection blood tests
- FDA approval status for daraxonrasib combination therapy
confidence 100%Sources used for this update (4)
- jen.jiji.com — Axios: Top secret meeting in Germany between US, Israel, and Arab commanders
- jen.jiji.com — Ukraine, FBI's warning: "Russia plans targeted assassinations in the US and Europe"
- www.scientificamerican.com — Blood test shows promise in detecting pancreatic cancer early—a 'Holy Grail' for the field
- pancan.org — PanCAN Announces 2026 Research Grant Recipients
-
FDA Grants Breakthrough Designation to Daraxonrasib
Federal regulators have awarded breakthrough therapy designation to daraxonrasib combined with chemotherapy for first-line metastatic pancreatic cancer. This development builds on the prior approval of the medication under the brand name Rasonque, which previously established a milestone by doubling median survival rates compared to standard chemotherapy while targeting difficult RAS mutations. Five competing drugmakers are currently pursuing similar personalized cancer vaccine therapies following recent melanoma trials by Merck and Moderna. The expanded designation highlights ongoing acceleration in targeted oncology pipelines aimed at addressing refractory tumors.
Why it matters
Pancreatic cancer remains one of the most challenging diagnoses in oncology due to historically low survival rates and a lack of effective treatments against aggressive genetic drivers. The previous approval of daraxonrasib offered a rare clinical advance for metastatic disease and sparked broader industry competition in tailored oncology drugs. Regulatory recognition via breakthrough status aims to expedite development pathways for therapies addressing severe unmet medical needs.
What is confirmed
- The FDA granted breakthrough therapy designation to daraxonrasib plus chemotherapy in first-line metastatic pancreatic cancer.
- Merck and Moderna lead the field in personalized cancer vaccines following a melanoma win last month.
Still unconfirmed
- Five different drugmakers are currently chasing Merck and Moderna in the cancer vaccine development race.
What to watch next
- Further clinical trial results from the five drugmakers pursuing personalized cancer vaccines
- Regulatory updates on combination therapies involving daraxonrasib and chemotherapy
confidence 90%Sources used for this update (5)
- jen.jiji.com — Italian Naval League, over 13,000 young people and the alliance with the Crusca to bring new generations closer to the sea
- jen.jiji.com — MotoGp, today San Marino Grand Prix - Live
- www.biospace.com — 5 drugmakers chasing Merck and Moderna in the cancer vaccine race
- jen.jiji.com — Serie A, today Inter-Udinese 0-0 - Live
- oncodaily.com — FDA Grants Breakthrough Therapy Designation to Daraxonrasib Plus Chemotherapy in First-Line Metastatic Pancreatic Cancer
-
FDA Approves Daraxonrasib for Metastatic Pancreatic Cancer
The FDA has approved daraxonrasib, marketed as Rasonque, for the treatment of metastatic pancreatic cancer. The drug targets RAS and doubles median survival rates compared to chemotherapy. While primarily approved for pancreatic cancer, early trials indicate the medication may also be effective against treatment-resistant lung cancer. This approval addresses one of the most difficult targets in oncology and provides a long-awaited treatment advance for patients with metastatic disease.
Why it matters
Pancreatic cancer has historically lacked effective targeted therapies. The introduction of RAS-targeting drugs like Rasonque represents a shift toward precision medicine in oncology. This development follows broader industry struggles with drug delivery and insurance access.
What is confirmed
- The FDA approved daraxonrasib for the treatment of metastatic pancreatic cancer.
- Daraxonrasib targets RAS in metastatic pancreatic cancer and doubles median survival versus chemotherapy.
- Daraxonrasib is marketed under the name Rasonque.
Still unconfirmed
- Daraxonrasib may help fight treatment-resistant lung cancer.
What to watch next
- Results from early trials regarding lung cancer efficacy
- Insurance coverage determinations for Rasonque
- Long-term survival data beyond the median survival increase
confidence 100%Sources used for this update (5)
- www.theglobeandmail.com — Globe Investor
- jen.jiji.com — Fuel prices, Council of Ministers approves 7-day extension of excise duty cut
- www.yahoo.com — A New Drug Takes Aim At One Of Cancer’s Most Difficult Targets
- www.medicalnewstoday.com — Pancreatic cancer drug may also help fight treatment-resistant lung cancer
- jen.jiji.com — Goodbye heat, mugginess finally out of play: this weekend all of Italy in green, how long will it last
-
Moonwalk Biosciences Secures $70M for Obesity RNAi Therapies
Moonwalk Biosciences has successfully raised $70 million in a Series B funding round to advance adipose-targeted RNAi obesity therapies, drawing new investment from Eli Lilly. This funding injection arrives as patients increasingly seek alternative treatments outside standard regulated health systems, fueling a broader boom in peptide and injectable care. Meanwhile, the biotechnology industry continues to face complex hurdles in drug delivery and insurance access following recent regulatory approvals for critical oncology treatments like Revolution Medicines' Rasonque.
Why it matters
The financing highlights intense commercial interest in novel therapeutic formats like RNAi and peptides as demand surges for advanced metabolic and obesity treatments. Companies are racing to develop next-generation interventions that bridge the gap between regulatory clearance and patient accessibility. Private capital continues to flow heavily into biotech firms developing targeted genetic and metabolic therapies.
What is confirmed
- Moonwalk Biosciences raised a $70M Series B for adipose-targeted RNAi obesity therapies.
- Eli Lilly joined Moonwalk Biosciences as a new investor.
Still unconfirmed
- Patients are looking beyond the regulated health system to address problems that doctors have struggled to treat.
What to watch next
- Clinical trial timelines for Moonwalk Biosciences adipose-targeted RNAi therapies
- Further investment or partnership announcements involving Eli Lilly and obesity drug developers
confidence 100%Sources used for this update (4)
- jen.jiji.com — Now, British-Israeli rabbi writes to UK PM criticizing hypocrisy in treatment of Israelis
- jen.jiji.com — "Artificial Intelligence can kill us all in 10 years", the researcher's warning
- www.smithsonianmag.com — Peptides Are All the Rage, Promising Miracle Cures and Makeovers Delivered by Injection. How Did We Get Here?
- en.wowtale.net — Moonwalk Biosciences Raises $70M for Adipose-Targeted RNAi
-
FDA Approves Rasonque for Pancreatic Cancer Amid Insurance Delays
The FDA approved Rasonque, a pancreatic cancer drug from Revolution Medicines, last month. While the drug marks the end of a long development quest, patients are currently struggling to access the treatment because insurance coverage often takes weeks to catch up with regulatory approval. Rasonque previously showed the ability to double median survival rates for pancreatic cancer patients who failed prior systemic therapies and is currently being investigated for efficacy in advanced lung cancer.
Why it matters
Revolution Medicines designed Rasonque for metastatic pancreatic adenocarcinoma. Researchers are now testing if the drug can treat other aggressive cancers or younger patient populations. This follows a broader medical effort to expand targeted cancer therapies.
What is confirmed
- The FDA approved Rasonque for the treatment of pancreatic cancer last month.
- Patients face delays in accessing Rasonque because insurance coverage can take weeks to follow FDA approval.
- Rasonque is developed by Revolution Medicines.
What to watch next
- Insurance providers' timelines for updating coverage for Rasonque
- Clinical trial results for Rasonque in advanced lung cancer patients
confidence 100%Sources used for this update (7)
- www.dailymail.com — How to ditch your blood pressure pills: Fed up with side effects or worried about the dangers? These are the simple changes that could help you get off the medication f…
- www.dailymail.com — As Thomasina Miers reveals she followed an intermittent low calorie diet during chemotherapy, why research suggests FASTING may boost some cancer treatments
- www.statnews.com — A breakthrough pancreatic cancer drug won approval. They still struggle to access it
- jen.jiji.com — Malagò's failed FIGC registration, Coni prosecutor rejects request for dismissal
- www.omanobserver.om — Race begins to more medicines like new pancreatic cancer drug
- jen.jiji.com — Oasis in Rome in 2027, two concerts in July on the Sun's calendar
- medicalxpress.com — Dual-drug approach burns out leukemia cells by pressing accelerator and brake simultaneously
-
Rasonque Trials Expand Following Success in Pancreatic Cancer
Rasonque, a daily pill developed by Revolution Medicines, is under investigation for advanced lung cancer after doubling median survival rates for pancreatic cancer patients who failed prior systemic therapies. Early clinical trials indicate one-third of lung cancer patients experienced tumor shrinkage. While originally designed for metastatic pancreatic adenocarcinoma, larger trials are now determining if the drug's efficacy extends to other cancer types. This effort is part of a broader medical push to identify and treat aggressive cancers, including those appearing in younger populations.
Why it matters
The FDA-approved drug targets specific mutations to treat advanced malignancies. Its success in pancreatic cancer established a baseline for efficacy in difficult-to-treat tumors. Researchers are now testing its versatility across different organ systems.
What is confirmed
- Rasonque is a daily pill developed by Revolution Medicines for metastatic pancreatic adenocarcinoma.
- The drug doubled median survival rates for pancreatic cancer patients who failed prior systemic therapies.
- One-third of patients with advanced lung cancer experienced tumor shrinkage in an early clinical trial.
What to watch next
- Results from larger trials regarding the drug's efficacy in lung cancer
- FDA updates on expanded indications for Rasonque
confidence 100%Sources used for this update (5)
- www.dailymail.com — The group of 'superfoods' that naturally lowers dangerously high blood pressure
- jen.jiji.com — Francesca Pascale celebrates Meloni government in Bari: "Berlusconi would be proud"
- jen.jiji.com — Back to school: ISS mini-guide for parents and children against anxiety
- www.usatoday.com — AI is helping get new medicines to patients sooner. Here's how
- www.dailymail.com — Sam thought her 'funny tummy' was caused by gluten or even IBS. Then she discovered the true culprit... a little-known cancer that's on the rise - and it's NOT c…
-
Pancreatic Cancer Drug Rasonque Shows Potential for Lung Cancer Treatment
The FDA-approved drug Rasonque, also known as daraxonrasib, is showing early potential to treat advanced lung cancer. In an early clinical trial, one-third of patients with advanced lung cancer experienced tumor shrinkage. The medication, originally developed by Revolution Medicines for metastatic pancreatic adenocarcinoma, is a daily pill that researchers call a landmark development. Larger trials are currently underway to determine if the drug's efficacy extends beyond pancreatic cancer. This follows the drug's success in doubling median survival rates for pancreatic cancer patients who failed prior systemic therapies.
Why it matters
Rasonque targets a gene previously viewed as undruggable, based on foundational work from University of Cincinnati researchers. The drug is an oral multi-selective RAS(ON) inhibitor. Its ability to potentially treat multiple cancer types suggests a broader application for RAS-inhibiting therapies.
What is confirmed
- The FDA approved Rasonque, or daraxonrasib, for adults with metastatic pancreatic adenocarcinoma who are ineligible for or failed one prior systemic therapy.
- Rasonque is a daily pill and an oral multi-selective RAS(ON) inhibitor.
- The drug doubled median survival rates in the RASolute 302 trial.
- Revolution Medicines developed the drug using foundational work from University of Cincinnati researchers.
Still unconfirmed
- One-third of patients with advanced lung cancer saw tumors shrink in an early clinical trial.
- Combining RAS(ON) inhibitors with other therapies could help patients overcome immunotherapy resistance.
- One individual remained cancer-free for more than two years using combined therapies.
What to watch next
- Results from the larger lung cancer clinical trials currently underway.
- Further data on the efficacy of combining Rasonque with immunotherapies.
confidence 90%Sources used for this update (6)
- jen.jiji.com — US Open, Guerrieri's dream ends: De Minaur dismisses the Italian in three sets and advances to the second round
- www.medicalbrief.co.za — FDA approval of landmark pancreatic cancer drug hailed by experts
- www.nbcnews.com — Newly approved pancreatic cancer drug shows promise in lung cancer
- jen.jiji.com — Tragedy in Finale Ligure: father, mother, and 15-year-old son found dead at home. Hypothesis of murder-suicide
- jen.jiji.com — De Martino returns with Affari Tuoi, the novelties: from the 'versatile' studio to Tommasino
- abcnews.com — Pancreatic cancer drug may hold promise for lung cancer as well, early study suggests
-
UC Researchers Helped Develop FDA-Approved Pancreatic Cancer Drug
The FDA approved Rasonque (daraxonrasib), an oral multi-selective RAS(ON) inhibitor for adults with metastatic pancreatic adenocarcinoma who failed or are ineligible for one prior systemic therapy. Developed by Revolution Medicines, the drug doubled median survival rates in the RASolute 302 trial. University of Cincinnati researchers contributed the foundational work for the treatment, which targeted a gene previously considered undruggable. Early-stage data published in Nature Communications suggests combining such therapies could help patients overcome immunotherapy resistance, with one individual remaining cancer-free for more than two years.
Why it matters
Pancreatic cancer has long lacked effective targeted therapies due to the difficulty of inhibiting specific genetic mutations. Rasonque's approval follows a national priority voucher filing that accelerated the process by five weeks. This development marks a shift in treating metastatic adenocarcinoma by successfully targeting the RAS gene.
What is confirmed
- The FDA approved Rasonque (daraxonrasib) for adults with metastatic pancreatic adenocarcinoma who are ineligible for or have failed one prior systemic therapy.
- Rasonque doubled median survival rates in the RASolute 302 trial.
- Revolution Medicines developed Rasonque.
- University of Cincinnati researchers helped lay the groundwork for the treatment.
What to watch next
- Clinical trial results for combination therapies to overcome immunotherapy resistance
- Further data on long-term survival rates beyond the RASolute 302 trial
confidence 100%Sources used for this update (5)
- www.wcpo.com — 'This is the beginning’ | UC researchers helped tackle an ‘undruggable’ target in pancreatic cancer
- finance.yahoo.com — MassLive’s Most Influential Innovators of 2026
- jen.jiji.com — Primark, 500th store opened in Pompeii: 8 million euros invested and 150 new jobs created
- www.sandiegouniontribune.com — Paul Sisson
- www.yahoo.com — Editorial Roundup: United States
-
FDA Approves Daraxonrasib for Metastatic Pancreatic Cancer
The FDA approved Rasonque (daraxonrasib), an oral multi-selective RAS(ON) inhibitor, for adults with metastatic pancreatic adenocarcinoma who are ineligible for or have failed one prior systemic therapy. Developed by Revolution Medicines, the drug doubled median survival rates in the RASolute 302 trial. The approval occurred five weeks after the company filed using a national priority voucher. While Rasonque targets a previously undruggable gene, separate early-stage trial results published in Nature Communications suggest combination therapies may help patients overcome immunotherapy resistance, with one patient remaining cancer-free for over two years.
Why it matters
Pancreatic cancer has long been considered intractable due to limited treatment options and resistance to immunotherapy. The approval of the first broad RAS-targeted therapy represents a shift in how physicians treat metastatic cases. This development follows decades of limited progress in improving survival times for the disease.
What is confirmed
- The FDA approved daraxonrasib for adults with metastatic pancreatic adenocarcinoma who have had at least one prior systemic therapy or cannot undergo multiagent systemic therapy.
- Rasonque is an oral pill that doubled median survival rates compared to chemotherapy.
- Revolution Medicines developed Rasonque as the first broad RAS-targeted therapy cleared for metastatic pancreatic cancer.
- The FDA granted approval roughly five weeks after the filing under a national priority voucher.
Still unconfirmed
- One patient in an early-stage combination therapy trial experienced a pathologic complete response and has remained cancer-free for more than two years without further treatment.
- Revolution Medicines reached a market valuation of $47 billion with shares hitting an all-time high above $224 on August 27, 2026.
What to watch next
- Clinical trial results for combination therapies targeting immunotherapy resistance.
- Long-term survival data from patients receiving Rasonque at institutions like Dartmouth.
confidence 95%Sources used for this update (4)
- medicalxpress.com — FDA approval opens new chapter in pancreatic cancer treatment
- medicalxpress.com — New combination therapy shows promise in metastatic pancreatic cancer
- finance.yahoo.com — Revolution Medicines (RVMD) Made Pancreatic-Cancer History. At $47B Valuation, the Market Already Assumed It
- www.news-medical.net — FDA approves daraxonrasib for metastatic pancreatic cancer following landmark clinical trial led by Dana-Farber
-
FDA Approves RASONQUE for Pancreatic Cancer Treatment
The FDA approved RASONQUE (daraxonrasib) on August 26, 2026, as a once-daily oral pill for pancreatic cancer. The drug doubled median survival rates compared to chemotherapy. Experts suggest the treatment could transform care for a disease long considered intractable, as it targets a gene previously viewed as undruggable. Patients at institutions including Dartmouth are among the first to receive the medication.
Why it matters
Pancreatic cancer is one of the deadliest forms of the disease and has remained difficult to treat for decades. This approval follows long-term research efforts to find a breakthrough for the condition.
What is confirmed
- The FDA approved RASONQUE (daraxonrasib) on August 26, 2026.
- RASONQUE is a once-daily oral pill.
- The drug doubled median survival rates compared to chemotherapy.
- The FDA announced the approval on Wednesday.
What to watch next
- Clinical data on long-term survival rates beyond the initial median doubling
- Expansion of the drug's approved use to other cancer types
- Development of additional medicines targeting the same gene pathway
confidence 100%Sources used for this update (12)
- WSJ — FDA Approves Drug for Pancreatic Cancer in Incredible Moment for Deadly Disease
- The New York Times — F.D.A. Approves Drug Poised to Transform Care for Pancreatic Cancer
- Fox News — FDA approves once-daily pill for deadly cancer after patients' survival rates nearly double
- Scientific American — U.S. approves breakthrough pancreatic cancer drug, heralding a new era for an intractable disease
- Pancreatic Cancer Action Network — FDA Approves RASONQUE™ (daraxonrasib)
- The New York Times — The Race to Develop More Medicines Like the New Pancreatic Cancer Drug
- Cleveland.com — For decades, researchers chased a breakthrough. Now it has finally arrived
- WMUR — Dartmouth patients among first to get new drug that fights pancreatic cancer
- www.today.com — FDA Approves ‘Game-Changing’ Pancreatic Cancer Drug
- www.gainesville.com — FDA approves pancreatic cancer drug Sasse credits with extending his life
- medicalxpress.com — FDA approves new treatment for hard-to-treat pancreatic cancer
- www.yahoo.com — The Drug That Finally Cracked Pancreatic Cancer’s “Undruggable” Gene
Community Sentiment: How do you assess this situation?
Voice your perspective · Real-time aggregated sentiment from the Live Feeds community